Abstract

This study evaluated a long-acting injectable (LAI) treatment program through examining the short and long-term outcomes of patients with schizophrenia or schizoaffective disorders receiving the LAI treatment in comparison with those receiving oral antipsychotic medications. Our findings provide insight into patient demographics, hospitalization rates, total medications, and dose ratios.

Author Details

Lin Lu, BSN, RN; Heeyoung Lee, PhD, APRN-BC -- School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Sigma Membership

Eta

Lead Author Affiliation

University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Type

Poster

Format Type

Text-based Document

Study Design/Type

N/A

Research Approach

N/A

Keywords:

Long-Acting Injectable Antipsychotic Medications, Patient Outcomes, Schizophrenia and Schizoaffective Disorders

Conference Name

30th International Nursing Research Congress

Conference Host

Sigma Theta Tau International

Conference Location

Calgary, Alberta, Canada

Conference Year

2019

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Acquisition

Proxy-submission

Additional Files

download (277 kB)

Share

COinS
 

Examining patient outcomes of receiving long-acting injectable antipsychotics

Calgary, Alberta, Canada

This study evaluated a long-acting injectable (LAI) treatment program through examining the short and long-term outcomes of patients with schizophrenia or schizoaffective disorders receiving the LAI treatment in comparison with those receiving oral antipsychotic medications. Our findings provide insight into patient demographics, hospitalization rates, total medications, and dose ratios.